Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rezolute, Inc. - Common Stock (NV)
(NQ:
RZLT
)
2.485
-0.185 (-6.93%)
Streaming Delayed Price
Updated: 10:56 AM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rezolute, Inc. - Common Stock (NV)
< Previous
1
2
3
4
5
6
Next >
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
December 24, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Which stocks are gapping on Wednesday?
↗
December 24, 2025
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Via
Chartmill
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
December 21, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
December 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
On Wednesday, there are stocks with unusual volume. Let's take a look.
↗
December 17, 2025
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via
Chartmill
Unusual volume stocks in Monday's session
↗
December 15, 2025
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.
Via
Chartmill
Unusual volume stocks in Friday's session
↗
December 12, 2025
Unusual volume stocks are being observed in Friday's session.
Via
Chartmill
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
December 11, 2025
From
Hagens Berman
Via
Business Wire
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
December 11, 2025
From
DJS Law Group
Via
Business Wire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
December 11, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
RZLT Stock Lost Nearly 90% Of Its Value Today – What Did The Company’s Latest Trial Reveal?
↗
December 11, 2025
Rezolute said that its Phase 3 sunRIZE trial of ersodetug to treat low blood pressure failed to meet its primary endpoint.
Via
Stocktwits
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
December 11, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
November 06, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
November 05, 2025
Webcast scheduled for Monday, November 10 at 12:00 pm EST
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
October 15, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 09, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
October 06, 2025
Via
Benzinga
Rezolute Inc (NASDAQ:RZLT) Reports Q4 FY2025 Results, Posts Wider-Than-Expected Loss Amid Strong Clinical Progress
↗
September 17, 2025
Rezolute Inc. reports Q4 FY2025 results, posting a net loss but maintaining a strong cash position of $167.9M to fund its Phase 3 clinical trials for congenital and tumor hyperinsulinism.
Via
Chartmill
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
September 17, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout
↗
September 17, 2025
Rezolute, Inc. is on track for its lead candidate to hit blockbuster status, but there are still risks and hurdles to overcome.
Via
MarketBeat
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
September 02, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
August 27, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
August 20, 2025
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug
From
Rezolute, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
August 13, 2025
Via
Benzinga
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 22, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
July 09, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
May 28, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
May 13, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
May 05, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
